<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Acute Lymphoblastic Leukemia PDX Models

>Most commercially available blood cancer patient-derived xenograft (PDX) models are transient in nature, and non-transferable through passages (not renewable), without disease symptoms or mortality. However, Crown Bioscience's PDX models for blood cancer are permanent, and allow the study of disease recurrence after initial treatment challenge and the efficacy testing of novel agents against drug resistance. The Crown Bioscience acute lymphoblastic leukemia (ALL) PDX collection covers a wide range including patient-relevant mutations e.g. BCR/ABL(+). More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
AL5503 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL5511 Acute Lymphoblastic Leukemia T AL5511 is an exceptional model designed to propel your research and development efforts in the fight against Acute Lymphoblastic Leukemia (ALL). During the critical pre-clinical phase, it is crucial to have a reliable model that accurately represents the disease and provides valuable insights into the effectiveness of potential oncology drugs. AL5511 offers an unparalleled platform to evaluate the efficacy, safety, and mechanisms of action of your drug candidates, aiding in the identification and optimization of the most promising therapies for ALL patients. Join us as we explore the remarkable capabilities of the AL5511 model, empowering you to make informed decisions and accelerate the development of life-saving oncology treatments. CLICK TO VIEW
AL5514 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL5518 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL5521 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL7015 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL7119 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL7142 Acute Lymphoblastic Leukemia T NA CLICK TO VIEW
AL7155 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL7174 Acute Lymphoblastic Leukemia T NA CLICK TO VIEW
AL7267 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL7442 Acute Lymphoblastic Leukemia T NA CLICK TO VIEW
AL7443 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL7447 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL7473 Acute Lymphoblastic Leukemia T NA CLICK TO VIEW
AL7475 Acute Lymphoblastic Leukemia T NA CLICK TO VIEW
AL8156 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW
AL8223 Acute Lymphoblastic Leukemia B NA CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login